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Sharona Hoffman and  
Andy Podgurski
I. Introduction
The unsustainable growth in U.S. health care costs is 
in large part attributable to the rising costs of phar-
maceuticals and medical devices and to unnecessary 
medical procedures.1 This fact has led health reform 
advocates and policymakers to place considerable 
hope in the idea that increased government support for 
research on the comparative effectiveness of medical 
treatments will eventually help to reduce health care 
expenses by informing patients, health care provid-
ers, and payers about which treatments for common 
conditions are effective and which are not.2 Compara-
tive effectiveness research (CER) has shown in some 
cases that expensive but commonly used treatments 
are significantly less effective than relatively inexpen-
sive alternatives.3 Critics warn, however, that CER will 
homogenize patient care, limit patient choices, and 
lead to improper health care rationing and even to the 
denial of lifesaving treatments.4 
In 2009, Congress allocated $1.1 billion in fund-
ing for CER, as part of the American Reinvestment 
and Recovery Act (ARRA).5 The Patient Protection 
and Affordable Care Act of 2010 (PPACA) embraced 
CER as an important health care reform initiative and 
established the Patient-Centered Outcomes Research 
Institute to oversee CER in the United States.6 CER 
represents a major public health enterprise, since 
public health, broadly defined, includes all “federal, 
state, and local governmental efforts to maintain and 
protect the health of the general population.”7
This article explores a novel application of CER 
that could enable physicians to make better treatment 
decisions for patients by invoking electronic queries 
of a large electronic health record (EHR) database. 
The query responses would summarize the outcomes 
of available treatments administered to patients with 
similar clinical characteristics.
We propose the development of a broadly accessible 
framework to enable physicians to rapidly perform, 
through a computerized service, medically sound per-
sonalized comparisons of the effectiveness of possible 
treatments for patients’ conditions. A personalized 
comparison of treatment effectiveness (PCTE) for a 
given patient (the subject patient) would be based on 
data from EHRs of a cohort of patients who are simi-
lar to the subject patient (clinically, demographically, 
genetically), who received the treatments previously 
and whose outcomes were recorded. The proposed 
framework would permit the patient’s physician to 
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order a computerized, retrospective study based on 
EHRs from the patient’s cohort within a large and 
representative database of deidentified EHRs. Experts 
would establish the parameters, outcome measures, 
methodology, and technical infrastructure for all 
PCTEs. The infrastructure would support PCTEs for 
various conditions.
The PCTE service could make a novel and valu-
able contribution to medical practice. PCTEs would 
focus on identifying, for a given patient, an appro-
priate reference group (cohort) of similar, previously 
treated patients whose EHRs would be analyzed to 
choose the optimal treatment for the patient at issue. 
This approach contrasts with the use of general clini-
cal prediction models8 that are intended to capture 
in a single mathematical construct the relationships 
among treatment choices, clinical and other predic-
tor variables, and prognoses for a large and diverse 
population of patients. PCTEs may employ statistical 
models, but these models would be fitted using data 
from the cohort of previously treated patients who are 
(or were) similar to the subject patient in clinically rel-
evant ways. Basing treatment effect estimates on such 
cohorts will enhance their predictive value. Using a 
PCTE service, doctors could submit a wide range of 
narrowly-tailored, treatment-effectiveness queries 
from their desktop computers.
PCTEs have unique potential to simultaneously 
improve the quality of health care, reduce its cost, and 
alleviate public concerns about rationing and “one size 
fits all” medicine.9 Therefore, they could serve as an 
important tool in promoting the goals of the health 
care reform initiative and make a significant contribu-
tion to public health. 
II. PCTE Building Blocks: Comparative 
Effectiveness Research and Electronic 
Health Record Systems
A. Comparative Effectiveness Research
Many physicians agree that medical decisions should, 
where possible, be based on a foundation of scientific 
evidence, although there is disagreement about the 
extent to which physicians’ freedom of action should 
be limited by such evidence.10 However, in many cases 
little is known about the comparative effectiveness of 
different treatments for a given medical condition. In 
the case of pharmaceuticals and medical devices in the 
U.S., one reason for this is that the FDA approval pro-
cesses generally do not require the effectiveness of a 
new product to be compared to that of existing ones; it 
is often sufficient for the manufacturer to provide evi-
dence of the product’s safety and efficacy as compared 
to a placebo.11 According to Alexander and Stafford,
 The FDA’s historical focus on common harms and 
on evaluating efficacy against placebo has led to 
testing in small, highly selected populations with 
limited comorbidities. In turn, these studies have 
failed to provide information most relevant to the 
clinical contexts in which FDA-approved drugs or 
devices are ultimately used.12
In 2009, the Institute of Medicine (IOM) recognized 
the need for expanded CER and proposed initial 
national priorities for it.13 The IOM report noted that 
randomized controlled trials (RCTs) are the “gold stan-
dard” for determining treatment effectiveness because 
they minimize bias in determining which patients 
receive treatment and which serve as controls. How-
ever, it recognized that RCTs cannot answer many 
comparative effectiveness questions and that observa-
tional data, such as that in EHRs, can help fill gaps 
in evidence when RCTs are not possible or are inad-
equate. Some commentators have posited that retro-
spective analysis of EHR data should play an impor-
tant role in bridging the “inferential gap” between “the 
paucity of what is proved to be effective for selected 
groups of patients versus the infinitely complex clini-
cal decisions required for individual patients.”14
PPACA enthusiastically embraced CER as a major 
health care reform initiative. The Act defines CER as 
“research evaluating and comparing health outcomes 
and the clinical effectiveness, risks, and benefits of 2 
or more medical treatments, services, and items….”15 
This article explores a novel application of CER that could enable  
physicians to make better treatment decisions for patients by invoking 
electronic queries of a large electronic health record database.  
The query responses would summarize the outcomes of available treatments 
administered to patients with similar clinical characteristics.
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CER is to be conducted through a wide variety of 
means, including clinical trials, observational stud-
ies, and any other appropriate methodologies.16 The 
goal of CER is to generate improved patient outcomes 
while maximizing the value derived from health care 
expenditures.17 PPACA emphasizes the importance of 
developing evidence concerning “variations in patient 
subpopulations” and of disseminating research find-
ings so that they can be used by those making health 
care decisions.18
Many commentators have expressed concern about 
the challenges of applying CER findings to achieve 
health care delivery improvements.19 CER would be of 
little worth if its results were not operationalized in 
the clinical setting. This article’s proposed PCTE tool 
offers a novel, creative mechanism to move CER dis-
coveries from bench to bedside so that it can be uti-
lized effectively by health care providers and patients. 
PCTEs would fit well within the CER goals articulated 
in PPACA. 
B. Electronic Health Records
An essential resource for CER generally and PCTEs 
in particular are electronic health records (EHR). 
The U.S. government has undertaken a major initia-
tive to computerize all Americans’ health records by 
2014. To that end, President Obama’s stimulus legisla-
tion, ARRA, dedicated $27 billion to the promotion 
of health information technology. Under ARRA, cli-
nicians may obtain payments of up to $44,000 from 
the Medicare incentive program and $63,750 per cli-
nician from the Medicaid program.20 In the years to 
come, EHR systems will transform medical practice 
in the United States. One of their many contributions 
is likely to be providing health care professionals with 
unprecedented research capabilities. 
Health information technology advocates contem-
plate the development of a National Health Informa-
tion Network (NHIN) of interoperable health infor-
mation systems so that necessary exchanges of health 
data can occur expeditiously. One of the potential ben-
efits of the NHIN is that it could greatly facilitate CER 
by providing medical researchers with access to what 
is in effect a massive database of deidentified EHRs.21 
This database could provide data that is invaluable for 
assessing the benefits and risks of different medical 
treatments in actual use. 
The importance of large electronic databases for 
research purposes is well recognized. A 2009 Price-
waterhouseCoopers report22 called for public-pri-
vate collaboration and a limited government role in 
enabling the private sector to collect, share, and use 
health data for secondary purposes, including CER. 
The Veterans Health Administration already uses its 
well-established EHR system to conduct extensive 
assessments of performance and outcomes and to 
operate an Evidence Synthesis Program.23 Likewise, 
the Food and Drug Administration (FDA) is planning 
to implement a national electronic system called the 
Sentinel Initiative that will enhance the FDA’s ability 
to monitor the safety of the products it regulates after 
they reach the marketplace. The FDA hopes to be able 
to send electronic queries to participating data hold-
ers such as health care providers and insurers, and 
obtain summary responses from them.24 Broad pro-
posals have also been entertained in the academic and 
health policy literature. For example, Lynn Etheredge 
recommended the establishment of both a National 
Database for Effectiveness Research Studies and a 
national network of new research registries and linked 
databases to “capture key data from millions of patient 
records so that comparative studies can cover all con-
ditions, treatments, and patient groups.”25
C. Will CER Necessarily Lead to Better Health Care?
There is no guarantee that CER studies will automati-
cally result in improved health outcomes. In the words 
of one commentator, “having better information is 
comparable to arriving at the base camp at Mount 
Everest. Clinicians, patients, managers, and policy 
makers need to work together to apply the results of 
comparative research appropriately and consistently 
if we are to reach the summit of reliable, evidence-
based, and patient-centered care.”26 Collecting data 
through research studies may be far easier than deter-
mining how they can be put to good use in the clinical 
setting.
Another concern is that CER will yield results that 
are not sufficiently individualized and that do not take 
into account all of the factors that make particular 
patients different from others. Thus, if doctors wrongly 
assume that certain CER findings are generalizable 
to all patients and base treatment decisions on these 
research results, they may make erroneous decisions 
in specific cases. Over-reliance on CER could lead 
doctors to ignore lifestyle, genetic, medical history, or 
patient preference factors that make a particular rec-
ommended therapy inappropriate for the individual 
in question.27
It is not surprising that treatment guidelines 
derived from estimates of average treatment effects for 
a diverse population can lead to suboptimal or even 
harmful results if they are applied naively to atypical 
subpopulations or individuals. This fact is illustrated 
by a 2009 retrospective study of the initiation of anti-
coagulation therapy with the drug warfarin in 5,052 
patients.28 The investigators found that a pharmaco-
genetic algorithm for estimating the appropriate ini-
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tial dose of warfarin, which considered both clinical 
and genetic factors, outperformed a standard dose of 
35 mg per week (and also outperformed an algorithm 
that considered only clinical factors), principally 
because the pharmacogenetic algorithm’s estimated 
doses were more efficacious (and presumably safer) 
for “outliers” — patients who required 21 mg of war-
farin or less per week or who required 49 mg or more 
per week. In an accompanying editorial, Woodcock 
and Lesko concluded that a “better understanding of 
individual differences in the response, either positive 
or negative, to medicines should be an overarching 
goal for pharmacotherapy over the next decade. Phar-
macogenetics has the potential to increase benefit and 
reduce harm in people whose drug responses are not 
‘average.’”29
CER is most controversial when it is discussed in 
the context of cost effectiveness analysis (CEA) of dif-
ferent treatments.30 Proponents of CEA, such as the 
American College of Physicians, see it as one valuable 
tool (among others) for informing those responsible 
for making decisions about medical expenditures.31 
Critics, however, warn that CEA will lead to homog-
enized medicine, in which the treatment that is most 
cost effective on average for a particular condition will 
be given to all patients with the condition, even if it is 
inappropriate for them. 
Some warn that a primary focus of CER will in 
fact be cost control. This could lead to care ration-
ing and denial if specific treatments are perceived as 
insufficiently cost effective or individuals are deemed 
unlikely to experience sufficient enhancements of life-
quality or longevity. PPACA aims to provide the pub-
lic with reassurance in this regard, stating explicitly 
that “[t]he Secretary shall not use evidence or findings 
from comparative clinical effectiveness research…in 
determining coverage, reimbursement, or incentive 
programs…in a manner that treats extending the life 
of an elderly, disabled, or terminally ill individual as 
of lower value than extending the life of an individual 
who is younger, nondisabled, or not terminally ill.”32
The best way to realize the potential benefits of CER 
in the face of legitimate public concerns is to foster a 
rational and appropriate demand for its results, based 
on individual physicians’ and patients’ perceptions 
of their own best interests. PCTEs constitute a CER 
approach that could well serve this goal. 
III. Personalized Comparisons of Treatment 
Effectiveness 
A. Overview
PCTEs would enable a patient’s physician to rapidly 
perform, through a computerized service, a medically 
sound personalized comparison of the effectiveness of 
possible treatments for the patient’s condition(s), the 
results of which would be provided, in readily compre-
hensible forms, to both the physician and the patient 
(or guardian). This personalized comparison would be 
based on the EHRs of a cohort of other patients with 
the same condition who are similar to the given patient 
in other ways that are relevant clinically, demographi-
cally, and perhaps genetically.
In technical terms, the proposed framework would 
permit the patient’s physician to order a computer-
ized, retrospective study based on EHRs from the 
patient’s cohort within a very large and representa-
tive database of deidentified EHRs. The results from 
this study would be adjusted statistically to take into 
account potential biases, confounding variables, and 
the results of well-regarded prior studies of the treat-
ments in question, especially randomized controlled 
trials. Admittedly, for some patients, no valid compar-
ison would be possible, e.g., because no suitable cohort 
could be identified in the EHR database. Before PCTEs 
could be conducted on behalf of patients with a par-
ticular condition, experts would establish the param-
eters, outcome measures, methodology, and technical 
infrastructure for them, as described in Part D. 
Thus, for example, a doctor who wishes to use a 
PCTE to help determine what treatment is best for a 
particular patient with hyperthyroidism would access 
an Internet service supporting PCTEs for hyperthy-
roidism patients. The physician would upload from 
his or her patient’s EHR the values of relevant clinical 
and demographic variables required for the PCTE. The 
PCTE service would then mine the database to identify 
EHRs of patients with similar values for those variables 
who were treated previously for hyperthyroidism. The 
records of patients who received particular treatment 
options would be sorted into corresponding treatment 
groups from which well-matched comparison groups 
would be selected, if possible. The treatment outcomes 
that were experienced by patients in the comparison 
groups (as characterized by an approved set of out-
come measures) would then be compared statistically. 
Finally, the PCTE service would present to the physi-
cian and patient, in understandable ways, results that 
accurately characterize the relative effectiveness of the 
treatments for the patient’s cohort. The entire process 
would be automated.
PCTE service providers would typically be com-
mercial enterprises that would profit from use of 
PCTEs. Health care providers could pay per query or 
be charged monthly rates for unlimited use of the ser-
vice. PCTE service providers should be motivated by 
the prospect of economic gain to provide high quality 
products and maximize user satisfaction. 
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The use of a computerized tool to facilitate individ-
ual treatment decisions has precedents. For example, 
Adjuvant! Online allows a doctor and cancer patient 
to input information about the patient and receive 
assistance in deciding upon the best course of treat-
ment after surgery.33 Adjuvant! Online uses com-
parative effectiveness research that has already been 
conducted to provide a treatment recommendation. 
Under our proposal, the PCTE service would conduct 
a comparative effectiveness analysis even if no formal 
CER study had been completed. 
Each PCTE would be based on a cohort of clinically 
similar patients rather than on a general model or a 
set of clinical practice guidelines. Thus, PCTEs would 
be uniquely well-suited to simultaneously improve the 
quality of health care, reduce its cost, and alleviate 
public concerns about rationing and “one size fits all” 
medicine.
There are numerous hurdles to successfully imple-
menting and operating the proposed framework for 
PCTEs, including technical, social, educational, eco-
nomic, ethical, legal, and political ones. Our proposal 
requires integrating cutting-edge developments in 
medicine, health information technology, computer 
science, and statistics. However, success is quite fea-
sible, and the potential long-term benefits, in terms of 
improved health, alleviated suffering, reduced health 
care costs, and reduced health disparities easily justify 
the investment required.
B. PCTEs and Personalized Medicine
Personalized comparisons of treatment effectiveness, 
as proposed here, constitute a form of personalized 
medicine. Personalized medicine can be defined as “the 
delivery of health care in a manner that is informed 
by each person’s unique clinical information; genetic, 
genomic, and other molecular/biological characteris-
tics; and environmental influences.”34
PCTEs would be consistent with this approach 
because they would be based on relevant patient 
variables whose values are recorded in EHRs, such 
as variables representing demographic information, 
clinical measures, aspects of medical or family history, 
and known risk factors, possibly including genetic or 
genomic factors.35 We use the term “covariates” to refer 
to the set of variables used in a PCTE that do not rep-
resent medical treatments or outcomes and whose val-
ues were acquired before any outcome measures were 
obtained. Ideally, the covariates, treatment variables, 
and outcome variables would capture, in suitable 
form, all of the information about individual patients 
that is necessary to accurately estimate effect differ-
ences for treatments of a given condition. There may 
be several, or even dozens, of covariates that are rel-
evant to a particular PCTE. We will also use the term 
“profile” to mean a complete, ordered set of covariates 
characterizing a patient. Different covariates will of 
course be appropriate for different conditions.
In a PCTE, a very large EHR database is searched 
to find a cohort for a patient needing treatment. Intui-
tively, this is the set of patients represented in the 
database who were treated for the same condition, 
who had similar profiles at the time they were treated, 
and whose treatment outcomes were recorded. Given 
an appropriate metric for measuring profile similarity 
or dissimilarity,36 the cohort of a patient Jane Doe may 
be defined as all patients whose profiles are within a 
numeric similarity threshold T of Jane’s profile. The 
threshold T should be chosen based upon a statistical 
analysis of the distribution of profiles and treatments 
for patients treated for Jane’s illness. The cohort should 
be reasonably large and relatively homogeneous in 
terms of covariate values. It should also be possible 
to select suitable treatment comparison groups from 
the cohort, each consisting of patients who received 
a given treatment. These groups should be approxi-
mately balanced with respect to both size and cova-
riate distribution. A number of techniques have been 
developed for constructing such matched groups.37 A 
personalized assessment of the relative effectiveness 
of two treatments can be obtained, for example, by 
estimating the average difference in treatment effects 
between matched individuals in the corresponding 
comparison groups.38
Note that PCTEs will be precluded for some patients 
because suitable comparison groups cannot be found 
(e.g., because the patients have unusual characteris-
tics). Several techniques exist to detect lack of balance 
among comparison groups.39 If multiple outcome mea-
sures exist for a condition, a PCTE may indicate that 
one treatment is best with respect to one measure and 
that another treatment is best by another measure. In 
this case the patient’s physician would help him or her 
interpret the results and decide on a course of action. 
PCTEs should be used to compare only established 
treatments or treatments that have been found to be 
safe and efficacious based on RCTs.
C. PCTEs and Observational Studies
Personalized comparisons of treatment effectiveness 
would rapidly provide doctors with actionable results, 
based on computerized observational studies. Obser-
vational evidence has been recognized by commenta-
tors as an important component of CER.40 Observa-
tional studies allow investigators to examine very large 
bodies of data based on treatments that were given to 
diverse populations of patients in real world clinical 
settings.
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Critics may object, however, to making treatment 
decisions based on nonrandomized studies. The main 
limitation of observational studies, and the main rea-
son that randomized trials are preferred for estimat-
ing treatment effects, is that since treatment selection 
(selection of patients to receive a particular treatment, 
or to serve as controls) is not explicitly randomized in 
an observational study, it may be influenced by con-
founding variables in ways that can seriously bias esti-
mated treatment effects. For example, suppose that 
doctors choosing between available treatments A and 
B for a particular serious condition tend to order treat-
ment A for younger, healthier patients and treatment 
B for older, sicker patients, because of concern about 
side effects of A in the latter individuals. If the esti-
mated benefit of treatment A over the entire patient 
population is greater than that of treatment B, then 
this may be due to the prior conditions of the patients 
who received the treatments and not to the superiority 
of treatment A. Doctors may not even be aware of their 
own subtle treatment biases, e.g., ones resulting from 
having treated a particular mix of patients in the past. 
Random treatment assignment, as in clinical trials, 
helps to avoid such biases by tending to yield compari-
son groups that are approximately balanced in terms 
of possible confounding factors. Even in clinical trials, 
however, the groups might not be representative of 
the overall population of patients with the condition 
because of bias in the recruitment of subjects, loss of 
subjects, and other factors.
Many physicians may be unaware that there has 
been substantial progress in redressing the limita-
tions of observational studies for clinical research 
and for causal inference generally. This progress has 
been spurred by a confluence of ideas and results 
from such diverse fields as epidemiology, econom-
ics, social science, statistics, and computer science.41 
The computer scientist Judea Pearl has presented a 
conceptual framework and a methodology for causal 
inference42 which unifies the major lines of causal 
inference research and which provides a foundation 
for conducting PCTEs. A key part of Pearl’s methodol-
ogy is formulating causal assumptions using ordinary 
scientific language and representing their structural 
aspects in graphical form. The result is called a causal 
model.
Even with state-of-the-art causal inference tech-
niques, there is reason to doubt whether treatment 
selection bias due to doctors’ and patients’ highly sub-
jective judgments about prognoses, frailty, pain, and 
other factors, made on the basis of information that is 
not completely captured in patients’ EHRs, can be ade-
quately controlled for based on standard EHR data.43 
In order to address this issue, EHRs intended for use 
in PCTEs could include physicians’ and patients’ own 
ratings of hard-to-measure factors like level of frailty 
or pain, e.g., on a numerical scale of one to ten.44 These 
ratings would require normalization through appro-
priate statistical adjustments to account for rater ten-
dencies, such as a consistent propensity to provide 
high scores. In any case, the computerized service that 
conducts a PCTE should subject the results to a proce-
dure called quantitative bias analysis before reporting 
it to the physician and patient.45 This analysis would 
aim to detect any evidence that the results were seri-
ously confounded by unknown variables, in which 
case the problem would be reported to the patient’s 
physician. 
D. PCTE Oversight Committees
To be widely accepted, PCTEs must be subject to rig-
orous processes for their design, approval, and long-
term monitoring. In light of space constraints, not 
every aspect of these processes can be detailed in this 
article, but a general operational framework is out-
lined below.
We envision that a commercial venture seeking to 
provide PCTE services for a particular disease would 
approach a leading professional organization for spe-
cialists in that area and request the formation of one 
or more PCTE Oversight Committees (POC) to over-
see the design and implementation of its PCTE ser-
vices. Thus, a company wishing to focus on a type of 
cancer could turn to the American Society of Clinical 
Oncologists; one interested in cardiology PCTEs could 
approach the American College of Cardiology; and a 
PCTE service provider for diabetes could work with the 
American Association of Clinical Endocrinologists. 
Pursuant to a negotiated contract, the PCTE service 
provider would pay the professional association a sum 
of money that would be used to support each POC. 
The association would then recruit POC members and 
pay them an annual honorarium for their work. POCs 
should consist of knowledgeable researchers, clini-
cians, statisticians, and patient advocates. In order to 
limit the amount of work each POC must do, a profes-
sional organization might create several POCs, each 
of which is tasked with addressing a subset of disease 
problems.
For each kind of PCTE, the POC and PCTE service 
provider, working together, should specify a causal 
model that represents the known or suspected causal 
relationships among treatments, covariates, outcome 
measures, and other factors that could influence treat-
ment results.46 Patient input should be obtained con-
cerning what outcome measures are most important to 
them. For example, these may involve not only disease 
cures, but also pain, recovery time, impact on personal 
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appearance, complication rates, and side effects. The 
POC and the PCTE service provider should also specify 
the techniques to be employed to measure similarity 
between patients and to identify cohorts. They should 
ensure that the EHR database to be used is adequately 
representative, and agree on a sound plan for validat-
ing the PCTE model and its implementation. The POC 
should oversee the implementation and evaluation of 
the PCTE service, approving or rejecting the results.
Large health care providers such as the Cleveland 
Clinic or Kaiser Permanente might wish to implement 
an internal PCTE service using their own patients’ 
EHRs. Such providers would not need to partner with 
a professional organization, but rather, could use their 
own experts. Nevertheless, they too would be required 
to utilize a POC that meets regulatory requirements, 
as described below. 
In other instances, business enterprises might wish 
to compete with existing PCTE service providers and 
to offer a different PCTE service, just as Google com-
petes with other search engine providers. Professional 
associations should be free to contract with and pro-
vide POC services to multiple commercial ventures. 
Associations should not have to establish entirely new 
POCs for different commercial ventures. POCs should 
be able to share the same causal model for a given 
condition and the same criteria for identifying cohorts 
with any commercial PCTE service providers, and the 
POC should inform all providers of refinements to the 
model or criteria. A POC would not, however, share 
a PCTE service provider’s proprietary design details 
with other service providers, and legal safeguards 
would have to be implemented to protect intellectual 
property rights and trade secrets. Sharing the same 
well-researched causal model and cohort identifica-
tion criteria with all PCTE service providers that are 
focusing on a particular condition would safeguard 
the consistency and quality of PCTE results. Patient 
outcomes should not depend upon the PCTE service 
used by their physician and should not suffer because 
some commercial ventures are forced to obtain data 
from second-rate sources. Moreover, because of the 
limited number of leading medical professional orga-
nizations, exclusive contracts could preclude competi-
tors from entering the market and thus violate anti-
trust law.47 
Use of professional associations should optimize the 
value of PCTEs and minimize the likelihood of con-
flicts of interest. If commercial PCTE service providers 
were to hire experts directly to formulate PCTEs, they 
might pressure such independent contractors to pro-
duce a large volume of work quickly, to the detriment 
of quality, in order to launch the service as soon as 
possible. Unlike commercial enterprises, professional 
associations would not be motivated by the prospect 
of large profits, because they would be limited to the 
specified contractual payment. In addition, profes-
sional organizations should have the interest of their 
members as their top priority, and therefore, they will 
wish to ensure that PCTEs are as helpful as possible to 
physicians and minimize medical malpractice expo-
sure. To that end, the organizations should ensure that 
all POC members have appropriate and current exper-
tise and are free of conflict of interest. 
Professional associations already have experience 
in formulating guidelines for clinicians. The National 
Guideline Clearinghouse lists over 2,500 clinical 
practice guidelines, many of which are published by 
associations.48
Because POCs would consist of individuals who 
chose to serve on the committees, their members can 
be expected to be dedicated to the work. The fact that 
POC members will be paid by the association should 
increase their accountability and sense of responsibil-
ity. For the sake of clarity, contracts between profes-
sional associations and PCTE service providers should 
specify conditions under which a contract will be 
deemed to have been breached (e.g., if a POC is not 
Unlike commercial enterprises, professional associations would not be 
motivated by the prospect of large profits, because they would be limited  
to the specified contractual payment. In addition, professional organizations 
should have the interest of their members as their top priority, and therefore, 
they will wish to ensure that PCTEs are as helpful as possible to physicians  
and minimize medical malpractice exposure. To that end, the organizations 
should ensure that all POC members have appropriate and current  
expertise and are free of conflict of interest. 
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formed by the association within a specified period of 
time or a particular phase of the project is not com-
pleted by a deadline). 
Much as research institutions maintain ongoing 
Institutional Review Boards (IRBs), professional 
associations would need to maintain POCs on a long-
term basis. Long-term monitoring of PCTE services 
would be necessary to ensure that results remain 
trustworthy in light of emerging research and input 
from physicians and patients who use the service. 
POCs should conduct continuing reviews, periodically 
surveying member physicians concerning their PCTE 
experiences as well as periodically auditing a sample 
of recent PCTEs and investigating the health status 
of the patients for whom they were conducted.49 In 
addition, physicians and patients who use the service 
should be able to report concerns about it to the rel-
evant POC, with the assurance that concerns will be 
considered carefully.
Government oversight over both POCs and PCTE 
service providers would be essential to ensure the safety 
and efficacy of PCTE services. Just as federal regula-
tions govern the composition of IRBs,50 the Depart-
ment of Health and Human Services (HHS) should 
formulate regulations concerning POC membership, 
requiring that they include qualified researchers, cli-
nicians, and community members who are patient 
advocates. The responsibilities of POCs should also be 
specified in regulations. 
PCTE service providers must be required by regula-
tion to utilize an appropriate POC to determine PCTE 
covariates and a causal model and to avoid conflicts of 
interest because of which commercial profit might be 
prioritized over patient care. In addition, HHS should 
be authorized to mandate periodic reports from 
PCTE service providers and to investigate suspected 
problems. 
E. Technical Infrastructure
Conducting PCTEs on a large scale requires designing 
and implementing a technically complex PCTE query 
service. Such a service would require a distributed soft-
ware system that would, when invoked by a physician 
in order to conduct a PCTE for a patient, retrieve (or 
prompt for) the data about the patient that is required 
by the PCTE’s causal model, mine the EHR database 
to identify a suitable cohort, execute causal inference 
procedures needed to characterize the relative effec-
tiveness of the treatments under consideration, and 
characterize statistical uncertainty about the results. 
The service’s user interface would be critically impor-
tant. It must guide the physician so he or she does 
not make mistakes that would invalidate the PCTE. 
It must also help the physician to properly interpret 
the results and warn of any limitations of the analysis. 
In essence, the user interface must serve the role of 
the physician’s own clinical research consultant. The 
entire PCTE service should be developed with adher-
ence to the best practices for software engineering, 
health informatics, and information security, and it 
should be required to undergo rigorous pre- and post-
deployment evaluation.51
The most realistic approach to developing a com-
prehensive PCTE service is to do so incrementally,52 
beginning with medical conditions that are both com-
mon and especially well suited to PCTEs. If the initial 
offerings were successful, the number of PCTE types 
available to physicians would be likely to grow over the 
years, as new PCTE service providers enter the market 
and as more POCs are formed to oversee the establish-
ment of PCTEs for additional conditions. 
Fortunately, it is not necessary to establish a nation-
wide network of interoperable EHR systems, such 
as the proposed NHIN, or a comprehensive solu-
tion to the problem of representing medical concepts 
unambiguously in concrete data structures53 before 
implementing PCTEs. The most important require-
ments for the EHR database to be queried are that its 
records be representative of the actual patient popu-
lation and that it be large enough to enable suitable 
cohorts to be identified for most patients. If a patient’s 
relevant characteristics are unusual, only a very large 
EHR database is likely to contain a sufficient number 
of records of patients with similar characteristics to 
enable valid statistical inferences to be made about 
treatment effects.
The required EHR database could be created from 
the EHRs of one large health care system or those 
of multiple health care providers who agree to share 
their EHR data and to adopt common data standards. 
A major health system such as the Cleveland Clinic or 
Mayo Clinic is likely to have a sufficiently large and 
diverse patient population to permit using its own 
EHR system as a database for conducting PCTEs, and 
health care networks will be motivated to implement 
such a service if it is shown to improve outcomes and 
to add to their profits. On the other hand, relatively 
small and resource-poor institutions that wish to 
conduct PCTEs will not be able to rely on their own 
EHRs alone. Instead, they will have to either partici-
pate in a federated system54 that searches the EHRs 
of multiple organizations or employ a PCTE service 
provided by a larger organization.
Carol Diamond and her coauthors note that, in the 
context of public health, a federated system obviates 
the need for different organizations to share their data 
about individuals and thereby eliminates a number of 
attendant problems, including privacy risks.55 Organi-
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zations participating in a federated system can share 
group-level summary data, such as means and propor-
tions, which are computed locally.
A federated system would not be unprecedented. 
DARTNet is an existing federated network that con-
sists of electronic health data from eight organiza-
tions representing more than 500 clinicians and over 
400,000 patients, which was created to facilitate 
observational CER about prescription medications 
and medical devices.56 DARTNet does not allow a full 
set of patient data to leave individual clinical sites; 
however, it permits queries that return deidentified 
data about individuals. 
To reduce privacy risks, a federated system for con-
ducting PCTEs could, at each participating organiza-
tion, identify a local “sub-cohort” (subset of a cohort) 
for a subject patient, based on the latter’s deidentified 
profile, but return to the PCTE service only summary 
statistics about the sub-cohort and possibly a fitted 
statistical model (e.g., a regression model) character-
izing the relationships between treatments, covariates, 
and outcome(s) for the sub-cohort. The PCTE service 
would combine the data characterizing each sub-
cohort (e.g., using multilevel modeling techniques)57 
to produce final predictions of treatment effects for 
the subject patient. The participating organizations 
would each need to support a common communica-
tion protocol and common set of statistical operations, 
but they would not have to provide one another with 
data about individual patients even in deidentified 
form.
F. Data Quality
Two of the greatest challenges to realizing the poten-
tial benefits of PCTEs are the quality and complete-
ness of the data contained in EHRs.58 Amanda Terry 
et al. list five characteristics of EHR data that affect 
their use in research:
 (i) providers decide where to put information 
(uniqueness of use); (ii) information may be 
entered in free-text form instead of being entered 
in defined fields or picked from a structured list of 
medical terms; (iii) providers use different terms 
for the same information (lack of standardiza-
tion); (iv) information may not be stored in a way 
that is readily searchable and (v) data that are not 
important to clinical care [but are important for 
research] may be missing.59
The authors identify two issues as central to data qual-
ity: (1) the need to code all presenting comorbidities 
and (2) developing criteria for identifying patients 
who have the specific condition to be studied.
A particularly noteworthy difficulty is that in 
some cases, treatment outcomes are not reported. A 
patient who receives medication and whose condition 
improves may not require follow-up and is unlikely to 
contact the doctor to report her satisfaction with the 
course of therapy. A lack of further patient visits may 
suggest treatment success, but it may also indicate 
that the patient is economically disadvantaged and 
does not have regular access to health care providers. 
An absence of definitive data in this regard could be 
problematic for PCTE purposes.60
Increasing use of electronic means for collecting 
patient data, such as remote patient monitoring,61 has 
the potential to mitigate problems with the complete-
ness and accuracy of EHR data. Furthermore, health 
care organizations that wish to offer PCTEs may be 
willing to create strong incentives for internal com-
pliance with standards for patient follow-up and data 
entry, because they view data quality as essential to 
their goals.
Ultimately, the federal regulations suggested above 
may need to address data integrity. It would be advis-
able for regulators to establish and enforce national 
standards for interoperability and data quality.62
G. Evaluation of PCTE Services 
It will also be important to conduct clinical trials to 
evaluate the safety and efficacy of particular PCTE 
services. To illustrate, a clinical trial could include 
breast cancer patients who are randomly assigned to 
two arms: one in which physicians use PCTEs and 
one in which they do not. Investigators must recog-
nize that the results of such studies will be somewhat 
obfuscated by the fact that physicians will be at liberty 
to disregard PCTEs in light of their own judgment or 
patients’ rejection of the recommended treatment. 
Therefore, researchers would need to evaluate not 
only the ultimate outcomes of patients in both study 
arms, but also the actual recommendations that the 
PCTEs made and physicians’ reasons for ignoring any 
of them. 
PCTE services should facilitate reporting by physi-
cians and HIT personnel of adverse events related to 
their use, such as serious usability problems or failures 
that lead to improper recommendations. This could be 
accomplished by incorporating a well-designed prob-
lem-reporting mechanism into the service, which could 
be invoked simply by clicking an icon. The occurrence 
of adverse events should promptly be shared with the 
POC and appropriate federal authorities for assessment. 
H. The Risks and Benefits of PCTEs
PCTEs are likely to raise concerns about privacy. 
Despite deidentification of records, many patients 
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may worry about confidentiality and the ability of 
third parties to trace sensitive information to them.63 
Consequently, careful attention should be paid to 
ensuring the integrity of the deidentification process 
and the security of EHR databases.64 In addition, 
questions may be raised concerning whether patients 
have a property right in their health information65 
and to what extent they should be asked to consent 
to their records’ use in PCTEs. For example, should 
patients have an opportunity to opt out of inclusion 
in the PCTE enterprise altogether? Should they be 
allowed to limit use of their deidentified records, such 
as by refusing to have them included in PCTEs relat-
ing to reproductive services? Would complying with 
such patient preferences be administratively feasible? 
These matters warrant further consideration.
PCTE service providers would also have to be trusted 
to maintain patient confidentiality. When processing 
PCTE queries, they would receive sensitive informa-
tion concerning patients and their medical conditions. 
Although patients would not be identified by name to 
the service provider, patients might become identifi-
able through various demographic details and the 
name of their treating physicians.66 Patients may worry 
that PCTE service providers will furnish search infor-
mation to health insurers, who in turn might refuse 
to pay for treatments in instances in which a physi-
cian deviated from PCTE recommendations. Potential 
disclosures to other third parties, such as employers, 
financial institutions, and marketers would also be of 
concern.67
PCTE service providers who have contracts with 
hospitals or health networks are likely to be consid-
ered business associates by the HIPAA Privacy Rule 
and to be bound by its confidentiality mandates.68 
However, PCTE service providers with a pay per query 
arrangement rather than contracts may not be covered 
entities. Consequently, the HIPAA Privacy Rule would 
need to be amended to state explicitly that PCTE ser-
vice providers fall within its scope.
Another obstacle to adoption of PCTEs may be phy-
sicians’ attitude toward them. Some physicians may 
object to giving a computerized service significant 
influence in treatment decisions, and some may even 
feel threatened by PCTEs. Physicians may also feel 
that they cannot afford the time required to initiate 
PCTEs and interpret the results. These concerns can 
be alleviated by a combination of skillful design of the 
service, strong evidence for the benefits of PCTEs, and 
appropriate incentives for using them implemented 
by physicians’ employers, hospitals, and others. 
It is also possible that PCTEs will exacerbate health 
disparities because not all patients will be able to pay 
for their use. If patients must pay out of pocket for 
PCTE queries, then only those with sufficient finan-
cial resources will be able to pay for the service. How-
ever, if PCTE use is shown to be cost effective because 
it improves outcomes and, when appropriate, leads 
clinicians to opt for less expensive treatments than 
they may have otherwise selected, then private and 
public insurers may well choose to cover the cost of 
the service.
There is good reason to hope that PCTEs will help 
lower health care costs by addressing the imbal-
ance of information that often exists between buyers 
and sellers of health services.69 Ideally, the results of 
PCTEs would lead physicians and patients to choose 
treatments that better control symptoms and cure 
diseases, thus reducing the need for further medical 
care. 
Patients who must absorb a significant portion of 
the cost of care because of high deductibles or co-
payments may also appreciate accurate information 
that allows them to make cost-effective decisions. For 
example, they may choose to forego a very expensive 
treatment and opt for a relatively inexpensive one that 
is only marginally less effective overall.
Physicians would utilize PCTE services only when 
they believe doing so would be beneficial, and we 
would not support institutional policies that require 
doctors and patients to follow PCTE recommenda-
tions. Doctors should maintain their professional dis-
cretion and patients their autonomy. PCTE services 
are meant to be only one tool in the medical toolbox, 
but they have the potential to be a very valuable asset 
for health care providers and to facilitate optimal 
treatment decisions. 
IV. Conclusion
This article proposes the development of a national 
framework to allow physicians to conduct electronic 
comparisons of treatment effectiveness (PCTEs) that 
are personalized with respect to individual patients’ 
clinically relevant characteristics. Each compari-
son would be based on the electronic health records 
of a cohort of clinically similar patients. Substantial 
groundwork must be laid before PCTEs can be made 
widely available. Given that EHR systems are not yet 
in general use,70 adequate EHR data about individuals’ 
long-term treatment effects is likely to be unavailable 
for some time. However, with proper design and over-
sight, PCTEs hold great promise to empower patients 
and physicians, reduce medical costs, and significantly 
improve public health. 
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